Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

The case revolves around Novartis' contention that MSN's generic contains small amounts of crystalline forms of the active ingredients in Entresto that would infringe a patent on the drug (No ...